Marketing Chinese plasma products in Finland
Ye, Dongchuan (2011)
Seinäjoen ammattikorkeakoulu
2011
All rights reserved
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:amk-2011120817739
https://urn.fi/URN:NBN:fi:amk-2011120817739
Tiivistelmä
The case company of this study is Shanghai Xin-xing Medicine Co. Ltd., the subsidiary of China General Technology Group in Shanghai City of China. The company manufactures plasma products. This study gives information about the company, their products and the outlook of marketing Chinese plasma products in Finland.
The goal of the study is to clarify the method of marketing Chinese plasma products in Finland. For that purpose one survey-questionnaire was sent to 20 main hospitals in different areas in Finland and two interviews with Finnish Red Cross Blood Services and Shanghai Xin-xing Medicine Co. Ltd. 5 hospitals gave responses to the questionnaire, the return rate turned out to be 25% as 5 responses to the questionnaire were received.
The analysis of the results from the questionnaire and the information from the interviews manifest that the market demand of plasma products in Finland keeps growing and there is potential market for Chinese plasma products, yet the company cannot expand into the Finnish market now, due to the lack of the EU-GMP (Good Manufacturing Practice) certificate.
Based on those information, a WHO-GMP or EU-GMP certificate is crucial to the company as to facilitate the process of achieving the potential Finnish market by establishing more stations of sole plasma collection to maintain sufficient raw material plasma, so that it would achieve the potential Finnish market in future years.
The goal of the study is to clarify the method of marketing Chinese plasma products in Finland. For that purpose one survey-questionnaire was sent to 20 main hospitals in different areas in Finland and two interviews with Finnish Red Cross Blood Services and Shanghai Xin-xing Medicine Co. Ltd. 5 hospitals gave responses to the questionnaire, the return rate turned out to be 25% as 5 responses to the questionnaire were received.
The analysis of the results from the questionnaire and the information from the interviews manifest that the market demand of plasma products in Finland keeps growing and there is potential market for Chinese plasma products, yet the company cannot expand into the Finnish market now, due to the lack of the EU-GMP (Good Manufacturing Practice) certificate.
Based on those information, a WHO-GMP or EU-GMP certificate is crucial to the company as to facilitate the process of achieving the potential Finnish market by establishing more stations of sole plasma collection to maintain sufficient raw material plasma, so that it would achieve the potential Finnish market in future years.